Derivative Compounds definition

Derivative Compounds means any and all compounds that are modified by chemical and/or molecular-genetic means from a Library Compound. Analogues of such compounds and their derivatives shall be included within the scope of Derivative Compounds.
Sample 1Sample 2Sample 3
Derivative Compounds means any analogs, homologs or isomers of a Designated Screening Compound, a Designated Shared Compound and/or an Independent Compound, as applicable. DESIGNATED COMPOUNDS means Designated Screening Compounds and Designated Shared Compounds. DEVELOPMENT shall mean the development of any Shared Product occurring from and after the filing of an IND, through and including approval of an NDA and any other Regulatory Approvals required for the Manufacture and Commercialization of such Shared Product in a country. Development shall not include Pre-Clinical Development activities. DEVELOPMENT COSTS shall mean all costs and expenses reasonably resulting directly from the Pre-Clinical Development of any Designated Shared Compound or Development of any Shared Product, as well as Overhead costs of the functions that directly support such Pre-Clinical Development or Development (as calculated in accordance with GAAP and using the same allocation methods that the party incurring such costs uses throughout its operations, but in all events excluding General Corporate Overhead), all as specified in the Development Plan and the Development Budget. DEVELOPMENT COSTS shall include, without limitation: (i) the Cost of Goods for the Designated Shared Compound used in such Pre-Clinical Development or Shared Product used in such Development (including early batches of the Shared Product for use in obtaining Regulatory Approval, to the extent not re-used later in commercial sales); (ii) direct costs for third party professional Pre-Clinical Development or Development services, including without limitation toxicology studies or clinical studies performed by third parties; (iii) direct charges for materials (including without limitation chemicals, animals and lab supplies); (iv) labor and materials *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 1 costs and fees incurred in connection with securing Regulatory Approvals; (v) labor and materials costs for the Development of the Manufacturing process for Shared Products and scale-up of such process; and (vi) the costs of FTEs dedicated to the foregoing activities. DIRECT ADMINISTRATIVE EXPENSES means the costs of invoicing, tracking and administering rebate and chargeback programs and product returns and of establishing and maintaining contracts with managed care organizations and governmental purchasers. DISTRIBUTION COSTS means the costs of distributing and shipping the Shared...
Sample 1
Derivative Compounds. Derivative Compounds means, with respect to any Licensed Compound, any compounds actually chemically derived, in one or more steps, by or on behalf of PRESIDIO, its Affiliates and/or Third Party sublicensees from such Licensed Compound, provided that, compounds derived by Third Party sublicensees or Third Party acquirers of PRESIDIO shall not constitute Derivative Compounds if such compounds are so derived (i) prior to the effective date of the grant by PRESIDIO of the sublicense to such sublicensee or the acquisition by such acquirer, as evidenced by contemporaneously prepared written records of such sublicensee or acquirer or (ii) without any use, direct or indirect, of (A) proprietary know-how disclosed to such Third Party in connection with the grant of the sublicense or the acquisition, or (B) Licensed Compounds (including Derivative Compounds) on which Development had previously been conducted by XTL or PRESIDIO, the results of which prior Development are identified to such Third Party in connection with the grant of the sublicense or the acquisition.
Sample 1Sample 2

Examples of Derivative Compounds in a sentence

  • Any Pharmacopeia employees assigned to work exclusively on Collaboration research projects shall also be subject to non-compete obligations, as set forth below, with respect to any Target with respect to which Collaboration research efforts directed to such Target are performed at Pharmacopeia (including, without limitation, the design and synthesis of Derivative Compounds based on Lead Compounds).

  • Pharmacopeia will also conduct primary screening assays of all such Derivative Compounds to determine activity against the applicable Target.

  • Such efforts may include the performance of further medicinal chemical research based upon such Selected Compounds and Derivative Compounds, as well as biological, pharmacokinetic and toxicology studies and other preclinical research activities.

  • Such reports will identify the chemical structure of any and all Derivative Compounds prepared by Pharmacopeia in performance of the Optimization Program (whether or not such compounds are identified as active against the Target), and all test data with respect thereto.

  • It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use such Lead Compounds and corresponding Derivative Compounds, during the term of this Agreement.

  • In performing each Optimization Program, Pharmacopeia shall undertake the synthesis of analogs and other Derivative Compounds based upon the relevant Lead Compounds.

  • This will include allocation of the medicinal chemistry FTEs, as well as additional FTEs to provide bioassay support, as necessary, for each Optimization Program to generate primary assay data for Lead Compounds and Derivative Compounds.

  • If Novartis does not exercise its Option for a Lead Program with respect to any Target that is a Novartis Reserved Target, then Infinity shall not, subject to Section 2.3.2(h), file any Patent covering such Lead Program (or otherwise shall assign such Patent to Novartis), or pursue further development or commercialization of such Lead Program, including any Derivative Compounds of such Lead Program, whether alone or with a Third Party.

  • With respect to all patent applications claiming Collaboration Technology, or any Derivative Compounds, Lead Compounds which are Hits, or Schering Derivatives, the filing Party shall give the non-filing Party an opportunity to review the text of such patent applications before filing, shall consult with the non-filing Party with respect thereto, and shall supply the non-filing Party with a copy of the applications as filed, together with notice of its filing date and serial number.

  • We can prosecute a provider who fails to notify us of a significant or notifiable event as set out in regulations.11 We will do this if: ◼ there is sufficient evidence to show that a notifiable event has occurred ◼ there is no evidence to suggest that we have received notification as soon as reasonably possible, and in any case within 14 days of the provider becoming aware of it ◼ any time in which the registered person may make representation has expired.


More Definitions of Derivative Compounds

Derivative Compounds means any derivatives or analogs for a Designated Compound, which have an IC(50) value against the Target of [*] or less, which (a) results from a chemical synthesis program based on the Designated Compounds or (b) is based on structure-activity data of the Designated Compound; PROVIDED, that any such program or data is in respect of a target protein that is greater than [*] homologous at the peptide level to the Target for which Mitsubishi designated such Designated Compound.
Sample 1
Derivative Compounds has the meaning given in Section 2.5(b).
Sample 1
Derivative Compounds means any analog, homolog or isomer of a Lead Compound, which has an IC50 value against the Screening Target of [*] micromolar or less, which (a) results from a chemical synthesis program based on the Lead Compounds or (b) is based on structure-activity data of the Lead Compound; PROVIDED, that any such program or data is in respect of a target protein from other bacterial or fungal organisms homologous in origin and biological function to the original Screening Target.
Sample 1
Derivative Compounds means, individually any JJPRD Derivative Compound or Sunesis Derivative Compound, and collectively JJPRD Derivative Compounds and/or Sunesis Derivative Compounds, as the case may be.
Sample 1
Derivative Compounds means any one or more Compound(s) made by or on behalf of Array, other than in the course of the Research Program, from the commencement date of the Research Program Initial Term until termination of the Agreement which (i) result from a chemical synthesis program based on a Collaboration Compound; (ii) are based on structure-activity data relating to Collaboration Compounds which are active or inactive in the Research Field; or (iii) are claimed in any patent application or patent filed by Amgen under Section 6.2 or by Array, which patent application or patent discloses any compound in subsection (i) or (ii) above.
Sample 1
Derivative Compounds means any analogs, homologs or isomers of a Designated Screening Compound, a Designated Shared Compound and/or an Independent Compound, as applicable.
Sample 1

Related to Derivative Compounds

  • Compounds means any or all of the following chemicals, as the context requires:

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Derivative Product means a written contract or agreement between the Authority and a Reciprocal Payor, which provides that the Authority’s obligations thereunder will be conditioned on the absence of (a) a failure by the Reciprocal Payor to make any payment required thereunder when due and payable, or (b) a default thereunder with respect to the financial status of the Reciprocal Payor; and:

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Product Technology means the Product Know-How and Product Patents.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Commercialized shall have corresponding meanings.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Development Candidate means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Commercializing means to engage in Commercialization and “Commercialized” has a corresponding meaning.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Program Technology means Program Know-How and Program Patents.

  • Interchangeable biological product means a biological product that the U.S. Food and Drug Administration has:

  • Milk product or "dairy product" means cottage cheese, dry curd cottage cheese, reduced fat cottage cheese, lowfat cottage cheese, cream, light cream, light whipping cream, heavy cream, heavy whipping cream, whipped cream, whipped light cream, sour cream, acidified sour cream, cultured sour cream, half-and-half, sour half-and-half, acidified sour half-and-half, cultured sour half-and-half, reconstituted or recombined milk and milk products, concentrated milk, concentrated milk products, skim milk, lowfat milk, frozen milk concentrate, flavored milk, eggnog, buttermilk, cultured milk, cultured lowfat milk, cultured skim milk, yogurt, lowfat yogurt, nonfat yogurt, acidified milk, acidified lowfat milk, acidified skim milk, low-sodium milk, low-sodium lowfat milk, low-sodium skim milk, lactose-reduced milk, lactose-reduced lowfat milk, lactose-reduced skim milk, aseptically processed and packaged milk, milk products with added safe and suitable microbial organisms, and any other milk product made by the addition or subtraction of milkfat or addition of safe and suitable optional ingredients for protein, vitamin, or mineral fortification. Unless a product is considered a milk product under this subdivision, milk product does not include dietary products, infant formula, ice cream or other desserts, cheese, or butter. Milk products include the following:

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.